Portfolio Manager Factsheet
Significant outperformance in June was generated by notable returns from four key stocks. Coherus Biosciences was lower in June after the company announced a significant delay in their development of a biosimilar version of Humira (adalimumab).
Worldwide Healthcare Trust PLC conducts its affairs so that its shares can be recommended by independent financial advisers (IFAs) to retail private investors. The shares are excluded from the Financial Conduct Authority's (FCA's) restrictions which apply to non-mainstream investment products because they are shares in a UK-listed investment trust.